Cell Cure Neurosciences, a subsidiary of BioTime, Inc., is a biotechnology company focused on developing cell therapies for retinal and neural degenerative disease. Our technology is based on human embryonic stem cells (hESC), cells which, for the first time in the history of medicine, open the door to industrial-scale manufacture of any cell type in the human body. Cell Cure is using these powerful stem cells to manufacture a particular cell type in the retina called the Retinal Pigment Epithelial (RPE) cell.
When RPE cells are lost as a result of aging, a disease called Age-Related Macular Degeneration (AMD) results. Our first product in development, designated OpRegen®, contains hESC-derived RPE to treat AMD. Unlike currently marketed products designed to treat only the wet form of AMD (10% of AMD patients), OpRegen® is being developed as a front-line therapy for the dry form of AMD (about 90% of AMD patients). Despite serving only the wet AMD market, the currently-marketed products have achieved >$5B in annual sales.
Cell Cure Neurosciences recently submitted an IND application with the FDA to commence human clinical trials of OpRegen® to treat the larger market of dry AMD for which there is currently no FDA-approved therapeutic.
Based in Israel, Cell Cure Neurosciences is a majority-owned subsidiary of BioTime, Inc. and has direct investments from Teva Pharmaceutical Industries, Ltd. and HBL-Hadasit Bio-Holdings, Ltd.